Arda Therapeutics develops therapies aimed at eliminating pathogenic cells that drive chronic diseases. The company utilizes single-cell data analysis to precisely identify and characterize these target cells. This approach informs the design of specific therapies engineered to selectively eliminate only the disease-driving cell populations.
Funding
$50.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
Chronic diseases and aging are often driven by specific pathogenic cells that contribute to disease progression. Current treatments often address symptoms without targeting the underlying cellular causes of these conditions.
Solution
Arda leverages single-cell data analysis to pinpoint and target the pathogenic cells responsible for driving chronic diseases and aging. By identifying these harmful cells, Arda designs therapies specifically aimed at eliminating them, addressing the root causes of these conditions rather than just managing symptoms. This approach focuses on selectively removing disease-causing cells while preserving healthy tissue. The company's methodology involves analyzing cellular data to understand the unique characteristics of pathogenic cells and developing targeted interventions to eradicate them.
Target Audience
Arda's primary focus is on individuals suffering from chronic diseases and age-related conditions, as well as researchers and healthcare providers seeking more effective and targeted treatment options.
Features
- Single-cell data analysis for identifying pathogenic cells
- Targeted therapy design for selective cell elimination